Mostrando 7 resultados de: 7
Filtros aplicados
Publisher
Clinical Cancer Research(2)
Cell Chemical Biology(1)
Endocrinology(1)
European Journal of Endocrinology(1)
Nature(1)
Origen
scopus(7)
Androstenedione is the preferred androgen source in hormone refractory prostate cancer Letter
OtherAbstract:Palabras claves:Autores:Richard J. Auchus, Sharifi N.Fuentes:scopus3β-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer
ArticleAbstract: Prostate cancer usually responds to androgen deprivation therapy, although the response in metastatiPalabras claves:Autores:Evaul K., Li R., Papari-Zareei M., Richard J. Auchus, Sharifi N.Fuentes:scopusAbiraterone acetate treatment lowers 11-oxygenated androgens
ArticleAbstract: Context: The human adrenal is the dominant source of androgens in castration-resistant prostate cancPalabras claves:Autores:Alyamani M., O'Day P.J., Richard J. Auchus, Sharifi N., Wright C.Fuentes:scopusAbiraterone inhibits 3β-hydroxysteroid dehydrogenase: A rationale for increasing drug exposure in castration-resistant prostate cancer
ArticleAbstract: Purpose: Treatment with abiraterone (abi) acetate prolongs survival in castration-resistant prostatePalabras claves:Autores:Chang K.H., Evaul K., Li R., Liu J., Richard J. Auchus, Sharifi N., Sharma K.K., Yoshimoto J.A.Fuentes:scopusDihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
ArticleAbstract: In the majority of cases, advanced prostate cancer responds initially to androgen deprivation therapPalabras claves:5-alpha-androstanedione, Abiraterone acetate, Hormonal therapy, Hormone resistance, Tumor metabolismAutores:Chang K.H., Li R., Papari-Zareei M., Richard J. Auchus, Sharifi N., Watumull L., Zhao Y.Fuentes:scopusRedirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
ArticleAbstract: Abiraterone blocks androgen synthesis and prolongs survival in patients with castration-resistant prPalabras claves:Autores:Abazeed M., Alyamani M., Balk S., Li J., Li Z., Richard J. Auchus, Rogacki K., Sharifi N., Taplin M., Upadhyay S.K.Fuentes:scopusSteroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities
ArticleAbstract: Galeterone is a steroidal CYP17A1 inhibitor, androgen receptor (AR) antagonist, and AR degrader, undPalabras claves:3βHSD, abiraterone, Androgens, CYP17A1, galeterone, metabolism, Prostate cancer, steroidsAutores:Alyamani M., Berk M.P., Li J., Li Z., Richard J. Auchus, Sharifi N., Tang J., Upadhyay S.K.Fuentes:scopus